ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last341 to 360 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI)77 of 16,263

101 of 8,152

-0.8 points

-1.0 to -0.5

24,415NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)44 of 16,263

63 of 8,152

-0.5 points

-0.7 to -0.3

24,415NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Predefined Clinically Relevant Disease Associated With RT-PCR-Confirmed RSV-Mediated ARI Over the Whole Study4 of 16,263

11 of 8,152

-0.1 points

-0.2 to -0.0

24,415NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Standard CPR vs Continuous Chest Compressions: Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge1,072 of 11,022

1,127 of 12,603

0.8 points

0.0 to 1.5

23,625NCT01372748

Continuous Chest Compressions vs AHA Standard CPR of 30:2

Synflorix Group vs Control Group: deaths from any cause19 of 11,798

26 of 11,799

-0.1 points

-0.2 to 0.1

23,597NCT00466947

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Synflorix Group vs Control Group: serious adverse events2,534 of 11,798

2,668 of 11,799

-1.1 points

-2.2 to -0.1

23,597NCT00466947

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Fluarix Quadrivalent vs mRNA-1010: deaths from any cause44 of 11,250

45 of 11,252

-0.0 points

-0.2 to 0.2

22,502NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Hypotension Decision Support vs Usual Care Group: deaths from any cause158 of 4,972

534 of 17,463

0.1 points

-0.4 to 0.7

22,435NCT02726620

Decision Support for Intraoperative Low Blood Pressure

Hypotension Decision Support vs Usual Care Group: serious adverse events541 of 4,972

1,811 of 17,463

0.5 points

-0.4 to 1.5

22,435NCT02726620

Decision Support for Intraoperative Low Blood Pressure

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With Unsolicited Adverse Events (AEs)1,495 of 11,200

1,351 of 11,210

1.3 points

0.4 to 2.2

22,410NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: serious adverse events495 of 11,200

518 of 11,210

-0.2 points

-0.7 to 0.3

22,410NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Zostavax™ vs Placebo: Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period69 of 11,094

61 of 11,116

0.1 points

-0.1 to 0.3

22,210NCT00534248

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Zostavax™ vs Placebo: serious adverse events243 of 11,094

233 of 11,116

0.1 points

-0.3 to 0.5

22,210NCT00534248

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine142 of 11,026

140 of 11,055

0.0 points

-0.3 to 0.3

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine85 of 11,026

75 of 11,055

0.1 points

-0.1 to 0.3

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine3 of 11,026

3 of 11,055

0.0 points

-0.1 to 0.1

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains70 of 11,026

70 of 11,055

0.0 points

-0.2 to 0.2

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine91 of 11,026

81 of 11,055

0.1 points

-0.1 to 0.3

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine45 of 11,026

40 of 11,055

0.0 points

-0.1 to 0.2

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains44 of 11,026

38 of 11,055

0.1 points

-0.1 to 0.2

22,081NCT05566639

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=18

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04908683-44a47b1c",
        "title": "Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI)",
        "summary": "77 of 16263 against 101 of 8152; risk difference -0.8 points, 95% interval -1.0 to -0.5; NCT04908683, A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
        "record": "/library/comparisons/NCT04908683-44a47b1c",
        "nct_id": "NCT04908683",
        "kind": "outcome",
        "participants": 24415,
        "risk_difference": {
          "value": -0.007654923845327753,
          "lower": -0.010459997404381596,
          "upper": -0.005175111830331038
        },
        "group_1": "77 of 16,263",
        "group_2": "101 of 8,152",
        "difference": "-0.8 points",
        "interval": "-1.0 to -0.5",
        "trial_title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older"
      },
      {
        "id": "NCT04908683-8d04ff99",
        "title": "Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)",
        "summary": "44 of 16263 against 63 of 8152; risk difference -0.5 points, 95% interval -0.7 to -0.3; NCT04908683, A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
        "record": "/library/comparisons/NCT04908683-8d04ff99",
        "nct_id": "NCT04908683",
        "kind": "outcome",
        "participants": 24415,
        "risk_difference": {
          "value": -0.005022636982133173,
          "lower": -0.007277082506567847,
          "upper": -0.0031027824186859367
        },
        "group_1": "44 of 16,263",
        "group_2": "63 of 8,152",
        "difference": "-0.5 points",
        "interval": "-0.7 to -0.3",
        "trial_title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=19",
  "request_id": "STgdyVCA2NOO2GfU"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?